TY - JOUR T1 - Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial JF - Lancet Y1 - 2015 A1 - Christophe Hézode A1 - Asselah, T. A1 - K R Reddy A1 - Hassanein, T. A1 - Berenguer, M. A1 - Fleischer-Stepniewska, K. A1 - P. Marcellin A1 - Hall, C. A1 - Schnell, G. A1 - Pilot-Matias, T. A1 - Mobashery, N. A1 - Redman, R. A1 - Vilchez, R.A. A1 - Stanislas Pol KW - Aged KW - analysis KW - California KW - Chicago KW - chronic HCV KW - deficiency KW - Disease KW - France KW - Gastroenterology KW - Genotype KW - HCV KW - Headache KW - hepatitis KW - Hepatitis C KW - hepatitis C virus KW - Hospitals KW - Infection KW - Intention KW - interferon KW - Interruption KW - Italy KW - Liver KW - Liver Diseases KW - medication KW - methods KW - NS5A inhibitor KW - Paris KW - Patients KW - pegylated KW - pegylated interferon KW - Philadelphia KW - Plasma KW - protease inhibitor KW - Research KW - Ribavirin KW - ritonavir KW - Rna KW - Safety KW - Spain KW - treatment KW - treatment-naive KW - Turkey KW - Universities VL - 385 SP - 2502-2509 IS - 9986 ER -